Acute-Onset Vitreous Hemorrhage of Unknown Origin before Vitrectomy: Causes and Prognosis
Table 2
Clinical characteristics of acute-onset vitreous hemorrhage (VH) of preoperatively unknown origin.
All
RVO
wAMD
Retinal break
Other
Number of eyes
169
77
21
50
24
0.001
Age (y)
63.64 ± 12.37
65.36 ± 9.82
73.29 ± 8.30
58.50 ± 11.78
60.63 ± 17.14
<0.001
Sex (male/female)
83/86
33/41
11/10
31/19
8/16
0.216†
Right/left
88/81
38/36
9/12
29/21
12/12
0.093†
Follow-up duration (mo.)
13.24 ± 14.52
11.34 ± 11.59
15.62 ± 19.19
15.56 ± 17.00
12.21 ± 12.49
0.360
Gauge of surgery
0.098†
20-gauge
19/169 (11.2%)
10/74 (13.5%)
5/21 (23.8%)
3/50 (6.0%)
1/24 (4.2%)
23/25-gauge
150/169 (88.8%)
64/74 (86.5%)
16/21 (76.2%)
47/50 (94.0%)
23/24 (95.8%)
Tamponade
<0.001†
No tamponade
56/169 (33.1%)
34/74 (45.9%)
4/21 (19.0%)
9/50 (18.0%)
9/24 (37.5%)
Air
55/169 (32.5%)
32/74 (43.2%)
1/21 (4.8%)
13/50 (26.0%)
9/24 (37.5%)
C3F8
24/169 (14.2%)
3/74 (4.1%)
1/21 (4.8%)
19/50 (38.0%)
1/24 (4.2%)
Silicone oil
34/169 (20.1%)
5/74 (6.8%)
15/21 (71.4%)
9/50 (18.0%)
5/24 (20.8%)
Systemic disease
Hypertension
92/169 (54.4%)
48/74 (64.9%)
13/21 (61.9%)
17/50 (34.0%)
14/24 (54.4%)
0.006†
Duration (y)
8.44 ± 7.85
8.55 ± 8.46
6.92 ± 5.39
6.90 ± 5.52
11.57 ± 9.76
0.329
Diabetes
20/169 (11.8%)
9/74 (12.2%)
2/21 (9.5%)
7/50 (14/0%)
2/24 (8.3%)
0.891†
Duration (y)
9.56 ± 8.46
7.56 ± 4.95
6.50 ± 4.95
12.71 ± 4.45
13.44 ± 9.50
0.658
Anticoagulant
51/169 (30.2%)
34/74 (45.9%)
3/21 (14.3%)
8/50 (16.0%)
6/24 (25.0%)
0.001†
RVO, retinal vein occlusion; wAMD, wet age-related macular degeneration. According to one-way ANOVA with the Bonferroni post test. †According to the Chi-square test.
